Emil Poulsen, MSc

Director, Drug Substance Development, CMC

Emil Poulsen, MSc, serves as Director, Drug Substance Development, CMC at Hemab and has more than 20 years of experience in the biotechnology industry across early- and late-stage process development. With experience in monoclonal antibodies, bispecific antibodies, antibody-drug conjugates and fusion proteins, he has successfully seen programs through Process Performance Qualification, submission and approval by EMA and FDA. Prior to joining Hemab, he worked at Biogen, Zymenex, CMC Biologics, Novozymes, Alpharma and was most recently an Associate Director of CMC Late-Stage Development Manufacturing at Genmab. He earned a Master of Science in Chemical Engineering and Biotechnology from the Technical University of Denmark.

Meet the Team

Hemab unites experts in clotting, patient care, and drug development to transform the lives of people with bleeding disorders

Leadership
Board
Team
Investors
novo holdings
RA Capital
HealthCap
Access Biotechnology
Deep Track Capital
Avoro Ventures
Invus
Rock Springs Capital
Maj Invest Equity
Hemab team photo
Hemab icon in larger circles

We’re building the ultimate clotting company.